Meeting
2023 ASCO Annual Meeting
Interim results from a phase I/II study of duvelisib PI3Kδγ inhibitor and nivolumab in patients with advanced unresectable melanoma who have progressed on anti-PD1 therapy.
Authors
Jingxiao Jin
University of Pittsburgh Medical Center Cancer Center, Pittsburgh, PA
Jingxiao Jin , Anjali Rohatgi , Andrew Gabrielle , Amy Rose , Melissa Wilson , Tullia C. Bruno , John M. M. Kirkwood
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT04688658
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 9540)
DOI
10.1200/JCO.2023.41.16_suppl.9540
Abstract #
9540
Poster Bd #
303
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Triplet therapy with pembrolizumab (PEM), encorafenib (ENC) and binimetinib (BIN) in advanced, BRAF V600 mutant melanoma: Final results from the dose-finding phase I part of the IMMU-Target trial.
First Author: Lisa Zimmer
Poster
2021 ASCO Annual Meeting
Multicenter phase I/II trial of encorafenib with and without binimetinib in combination with nivolumab and low-dose ipilimumab in metastatic BRAF-mutant melanoma.
First Author: Max Jameson-Lee
Poster
2020 ASCO Virtual Scientific Program
FDG-PET metabolic tumor volume in advanced melanoma treated with ipilimumab and nivolumab (ipi/nivo).
First Author: Amir Iravani
Poster
2018 ASCO Annual Meeting
Phase I/II study to evaluate the safety and efficacy of tenalisib, a novel PI3K δ/γ dual inhibitor in combination with pembrolizumab in patients with relapsed/refractory classical Hodgkin lymphoma.
First Author: Rod Ramchandren